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Abstract
Aberrant activation of the Wnt signalling pathway is required for tumour initiation and sur-
vival in the majority of colorectal cancers. The development of inhibitors of Wnt signalling
has been the focus of multiple drug discovery programs targeting colorectal cancer and
other malignancies associated with aberrant pathway activation. However, progression of
new clinical entities targeting the Wnt pathway has been slow. One challenge lies with the
limited predictive power of 2D cancer cell lines because they fail to fully recapitulate intratu-
moural phenotypic heterogeneity. In particular, the relationship between 2D cancer cell biol-
ogy and cancer stem cell function is poorly understood. By contrast, 3D tumour organoids
provide a platform in which complex cell-cell interactions can be studied. However, complex
3D models provide a challenging platform for the quantitative analysis of drug responses of
therapies that have differential effects on tumour cell subpopulations. Here, we generated
tumour organoids from colorectal cancer patients and tested their responses to inhibitors of
Tankyrase (TNKSi) which are known to modulate Wnt signalling. Using compounds with 3
orders of magnitude difference in cellular mechanistic potency together with image-based
assays, we demonstrate that morphometric analyses can capture subtle alterations in orga-
noid responses to Wnt inhibitors that are consistent with activity against a cancer stem cell
subpopulation. Overall our study highlights the value of phenotypic readouts as a quantita-
tive method to asses drug-induced effects in a relevant preclinical model.
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Introduction
Aberrant canonical Wnt/β-catenin signalling, as a result of activating mutations within the
pathway, has a prominent role in the initiation and progression of colorectal cancer (CRC) [1,
2]. A number of feedback loops control β-catenin turnover and Wnt activation. In the absence
of a Wnt ligand the multi-protein β-catenin destruction complex, formed of AXIN1/2, Adeno-
matous polyposis coli (APC) and glycogen synthase kinase (GSK3β), mark β-catenin for deg-
radation [3]. As a result, the accumulation and subsequent translocation of β-catenin to the
nucleus is inhibited, preventing the downstream activation of target genes [4]. Components of
the destruction complex are also tightly regulated. AXIN1 and AXIN2 are concentration-limit-
ing components of the destruction complex. Levels of AXIN1/2 are post-transcriptionally reg-
ulated by tankyrases (TNKS1 and TNKS2), members of the poly (ADP-ribose) polymerases
(PARP) family of enzymes, which enhance Wnt signalling by targeting AXIN1/2 for degrada-
tion [5].
The inhibition of Wnt signalling has been validated as a means of blocking tumour growth
in many cancer models [6, 7]. Small molecule inhibitors of TNKS1 and TNKS2 have been
shown to reduce Wnt signalling in intestinal cancer cell lines and have been suggested to pre-
vent tumour growth due to their ability to stabilise AXIN1 and AXIN2 levels and as a result, to
inhibit β-catenin mediated transcription [5, 8–16]. However, the progression of TNKSi into
clinical trials has been restricted due to significant issues of intestinal toxicity within in vivo
models, emphasising the important role of Wnt signalling in adult tissue homeostasis [17]
[18]. Furthermore, the TNKSi described above reduced colorectal cancer cell numbers in 2D
culture, but did so with relatively low effect sizes by comparison with their ability to reduce lev-
els of Wnt/TCF-dependent transcription in the same cell lines. Similar partial-efficacy cell line
responses were observed during the development of inhibitors of the CDK8 and CDK19
kinases, suggesting that growth in 2D cell culture may not be an optimal readout for com-
pounds that are anticipated to target cancer stem cells [7].
To date, most preclinical in vitro studies have relied on the use of conventional 2D cultures
of cell lines. Whilst cancer cell lines can be usefully used to study pathway deregulation, they
frequently fail to be predictive when used as readouts of anti-tumour efficacy [19]. It is well
recognised that immortalised 2D cell lines adapted to growth on plastic poorly represent the
intricate cellular cross-talk present in tumours. In particular, they are unable to recapitulate
the inter-cellular interactions that form cancer stem cell niches and, as a consequence, such
models fail to fully reflect in vivo results.
3D tumour organoids have been shown to provide a more complex insight into tumour
cell-cell interactions [20, 21] and have been recognised as models with the potential to bridge
the gap between in vitro and in vivo preclinical studies. Organoids that have never been
adapted for growth on plastic have been cultured from multiple tumour types, and have been
shown to better represent the genetic diversity of distinct tumour subtypes than 2D cell lines
[22]. Organoids derived from genetically-engineered mice in which the Wnt pathway had
been oncogenically-activated accurately predicted subsequent in vivo responses to inhibitors
of the CDK8 and CDK19 kinases, while 2D cell culture only showed partial-efficacy [7]. Orga-
noids have been further shown to predict patient responses and might in future be used in the
clinic in personalised medicine [23].
The biological and phenotypic complexity of 3D primary organoid cultures allow, in princi-
ple, the assessment of compound activity against a subset of inter-cellular signalling that is cen-
tral to tumour growth. However, most uses of organoid assays to date have relied on fixed
end-point metabolic assays (e.g. ATP-level quantification) that aggregates responses in every
cell within a population of organoids. To fully exploit the potential of organoid assays, analysis
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platforms need to yield quantitative data that can clearly represent compound-induced effects
on signalling pathways whose outputs are complex, whilst simultaneously maintaining usabil-
ity in a high throughput format.
In this work, we generated CRC patient-derived organoids and studied their responses to
Tankyrase inhibitors (TNKSi). Using metabolic end point assays, tankyrase inhibition showed
partial efficacy, reflecting a limited reduction in the growth of TNKSi-sensitive organoids.
Closer examination of organoid responses suggested that TNKSi altered the ratio of stem-like
to differentiated cell populations. This subtle effect on the cellular composition of organoids
was best reflected by multiparametric imaging analysis of organoids that was nonetheless com-
patible with high throughput analysis. Our findings demonstrate the potential of a phenotypic
approach to assess drug-induced phenotypes in a preclinical setting, which may be applicable
to a wider range of therapeutics that target cancer stem cell biology and niches.
Materials and methods
Materials
Corning Growth factor-reduced Matrigel was purchased from VWR (#734–1101). Cell culture
media were purchased from Invitrogen Life Technologies, and cell culture plastics from Nunc
unless otherwise stated. All TNKSi compounds were supplied and synthesized by Merck
Healthcare KGaA (Darmstadt, Germany). All stock solutions of compounds were reconsti-
tuted in DMSO. Activity of each compound had been assessed prior to shipping using a cell-
based immunobead assay to determine TNKSi potency based on the ability of the inhibitors to
stabilise the AXIN2 [24]. The determined EC50 values of 2 nM, 36 nM and 319 nM (Fig 2A)
were determined for C1, C2, and C3 respectively.
Human tissue
Surgically resected patient materials were obtained from University Hospital of Wales by the
Wales Cancer Bank with written informed ethical consent from male and female patients
(>16 years of age, above the UK age of valid consent) with known or suspected malignant dis-
ease and anonymised (WCB project reference #12/001). The Wales Cancer Bank has ethics
approval as a Research Tissue Bank from the Wales Research Ethics Committee 3 (reference
16/WA/0256), and is licensed by the Human Tissue Authority under the UK Human Tissue
Act (2004) to store human tissue, taken from the living, for research (licence 12107) [25].
These approvals cover the collection of samples (including written consent), processing and
storing samples across multiple collection and storage sites. All patient derived material was
handled in concordance with HTA regulations. Histological sections of patient tissue were
imaged at University Hospital Wales and remained anonymised.
Organoid culture
The isolation of tumour organoids from patient material was processed as previously described
by Sato et al., [20] with some refinements outlined below. Briefly, following surgical resection,
tumour samples were obtained and stored in Hibernate A medium (Life Technologies) at 4˚C.
Tissue pieces were dissected to remove connective tissue and chopped to pieces approximately
2 mm in diameter. Following dissection, carcinoma pieces were washed in PBS then digested
enzymatically with Collagenase and Dispase for 30 minutes at 37˚C. Once digested, tissue was
triturated in PBS at room temperature to release cell fragments from tissue. Cell fragments
within the supernatant were then centrifuged for 5 min at 100 rcf, at 4˚C. Cell pellets were
resuspended in Advanced DMEM/F12 supplemented with 1% GlutaMAX, 1% HEPES buffer
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solution and 1% Penicillin/Streptomycin, then filtered (70 μm). Collected tissue fragments
were counted and plated at a density of 1000 cell fragments per 50 μL of Growth Factor
Reduced Matrigel (BD Biosciences) in 24 well plates (Nunc). Following Matrigel polymerisa-
tion, cells were overlaid with 500 μL of either “7+” or “Full” media and replenished every 4
days. ‘7+’ Media conditions consisted of Advanced DMEM/F12 supplemented with penicillin/
streptomycin, 2mM GlutaMAX, 10 mM HEPES,1 X B27 supplement, 1 X N2 supplement (all
Life Technologies), 1 mM N-acetyl-L-cysteine (Sigma-Aldrich). The following additional
niche factors were added to generate “Full” media: 50 ng/ml mouse recombinant EGF (Life
Technologies), 100 ng/ml mouse recombinant Noggin (Peprotech), 10% RSpo-1 conditioned
medium [26], 40% Wnt-3A conditioned medium [20], 500 nM A83-01 (Tocris) and 10 μM
SB202190 (Sigma). 10μM Y-27632 (Tocris) was also added to media for the first three days of
culture. Optimal media was determined for each tumour organoid line on the basis of condi-
tions that favoured the most efficient growth of organoids. For subsequent passaging, mainte-
nance in culture and analyses, the most favourable media condition was used. All culture were
maintained in humidified incubators at 37˚C, 5% CO2.
DNA extraction
DNA extraction from organoid cultures was carried out using a QIAamp DNA Mini Kit (Qia-
gen) following the manufacturer’s instructions. Purified DNA quality was initially assessed
using a Nanodrop1000 (Thermo Fisher). Patient blood samples were processed by the Wales
Cancer Bank (WCB), genomic DNA was extracted from 4 ml of whole blood using the Chema-
gicSTAR automated cell lysis and DNA extraction workstation (Hamilton Company) housed
within the All Wales Medical Genetics Service (AWMGS) laboratory. Both DNA samples were
then passed to the Wales Gene Park for quality control, library preparation and sequencing.
Whole exome library preparation
The following was carried out by the Wales Gene Park. Genomic DNA was initially quantified
using the Qubit1 (Life Technologies) and the samples were serially diluted to 5 ng/μL. 50ng
of gDNA was used as the input and the sequencing libraries were prepared using the Illu-
mina1Nextera Rapid Capture Enrichment kit (Illumina Inc.). The steps included tagmenta-
tion of gDNA, clean-up of the tagmented DNA, amplification, clean-up of the amplified DNA,
hybridisation of probes, capture of the hybridized probes, second hybridization of probes, sec-
ond capture, clean-up of the captured library, amplification of enriched library, clean-up of
the enriched library and finally validation of the complete library. The manufacturer’s instruc-
tions were largely followed with extra quantitation steps prior to the hybridization of the
probes to ensure that approximately 500 ng of each sample was pooled. The libraries were vali-
dated using the Agilent 2100 Bioanalyser and a high-sensitivity kit (Agilent Technologies) to
ascertain the insert size, and the Qubit1 (Life Technologies) was used to perform the fluoro-
metric quantitation. Following validation, the libraries were normalized to 10 nM, pooled
together and clustered on the cBot™2 following the manufacturer’s recommendations. Pools
were then sequenced using a 75-base paired-end (2x75bp PE) dual index read format on the
Illumina1HiSeq4000 according to the manufacturer’s instructions.
Whole exome sequencing and mutation calling
Reads were mapped to the human reference genome (GRCh37) with BWA version 0.7.10 [27],
and duplicate reads were removed with Samtools version 0.1.19 [28]. Base quality score recali-
bration was performed using GATK’s BaseRecalibrator (GATK version 4.0.3.0, [29, 30] and
GATK’s Mutect2 was used to call somatic variants (tools found at https://software.
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broadinstitute.org/gatk/). Variants were annotated with Variant Effect Predictor version 91.3
[31], using a cached version of ensemble v91. A custom Perl script was used to extract genes of
interest from annotated variant files. Default parameters were used for all software unless oth-
erwise stated. All of the calls reported were cross-checked against the cBioportal database
(https://www.cbioportal.org) and are those found to have been previously described within the
COSMIC database (https://cancer.sanger.ac.uk/cosmic) as being “likely oncogenic”.
Immunohistochemistry
Formalin-fixed paraffin embedded histological sections of patient tissue were processed,
imaged and analysed by the Histopathology unit at University Hospital Wales. For organoid
histology, organoids embedded within Matrigel were fixed with 4% paraformaldehyde for 15
min at room temperature. Organoids were then lifted from wells and washed several times
with PBS prior to embedding within low melting-point agarose, followed by dehydration, par-
affin embedding, sectioning and Hematoxylin+Eosin (H&E) staining. Images were acquired
on an Olympus Dp26 microscope.
Western blot detection
Organoids were harvested from 6 X 50 μL blobs of Growth factor-reduced Matrigel using Cell
Recovery Solution (Corning) for 1 hour on ice. Total protein was extracted from organoids by
addition of 500 μL of lysis buffer to whole organoids (0.02 M Tris-HCl, 2 mM EDTA, 0.5% v/v
NP-40 (IPEGAL) in ddH2O containing 1x PhosSTOP phosphatase inhibitor (Roche) and 1x
complete Protease Inhibitor Cocktail (Roche)). The lysates were centrifuged at 8000 rcf for 15
min and proteins harvested in the supernatants. Protein content was measured using a BCA
protein assay kit (Pierce). Samples were resolved on Novex NuPAGE 4–12% Bis-Tris PAGE
gels, and then blotted onto nitrocellulose membranes using the Invitrogen iBlot Dry Blotting
cassette system.
Blots were blocked at room temperature for 1 h in 5% w/v milk powder in wash buffer, Tris
buffered saline (TBS) plus 0.2% Tween 20. Primary antibodies were diluted in blocking buffer
and incubated overnight at 4˚C. After washing the blots were incubated with HRP-conjugated
secondary antibodies for 1 h at room temperature. Bands were visualized using the enhanced
chemoluminescence (SuperSignal West Dura; Pierce). Antibodies and dilutions: TNKS1/2
(Santa Cruz (Tnks1/2 E-10) SC-365897, 1:500), Axin2 (Cell Signalling Technologies 76G6,
1:500) (# 2151)), β-actin (Sigma (AC-74) A2228, 1:10,000), anti-mouse or anti-rabbit HRP-
conjugated antibodies (GE Healthcare, 1:5000).
Organoid viability measurements
Organoids in culture were gently dissociated to near-single cell populations using TrypLE
(Life Technologies) before resuspension within growth factor-reduced Matrigel, and dispensed
into white clear bottomed 96 well plates in 9 μL Matrigel per well (400 cells/ μL of Matrigel).
Following Matrigel polymerization, a 9-point 2-fold dilution range of compounds were diluted
in tailored growth medium and dispensed within each well. DMSO was used as a negative con-
trol at a final concentration of 0.1%. Following a six day exposure to compounds, Cell Titer
Glo 3D (Promega) reagent was applied as per the manufacturer’s guidelines for an endpoint
readout. Relative Luminescence values were obtained on a BMG Fluostar plate reader. Dose
response curves and EC50 values were obtained using Microsoft Excel with XLFit plug-in (Ver-
sion 5.4.0.8).
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High content fluorescence microscopy
Organoid lines previously established in culture were split to single cells using TrypLE (Life
Technologies) and seeded within growth factor-reduced Matrigel (Corning) in black clear-bot-
tomed 384 well plates, at 12 μL per well, at a density of 400 cells/ μL Matrigel. Upon polymeri-
sation of Matrigel, growth media containing a titration range of individual compounds or
DMSO controls were added to each well prior to incubation at 37˚C. Organoids were exposed
to compounds for a total of six days prior to fixation in a fix-and stain solution containing 4%
para formaldehyde (Sigma Aldrich), 0.2% Triton X-100 (Sigma Aldrich) 0.25μM rhodamine-
phalloidin (Sigma Aldrich) and 1 μg/ml Hoechst 33258 (Sigma Aldrich) in PBS at 4˚C for 24 h.
After staining, plates were washed with PBS and sealed. Imaging was performed on an Ima-
geXpress1 high-content micro confocal platform (Molecular Devices). A total of 25 Z-stack
images were acquired at 10 μm steps through the focal plane per well of a 384 well plate using a
4 X objective. Image stacks were captured from both TRITC channel (EX = 548, EM = 645)
and DAPI channel (EX-380, EM = 435) to detect both rhodamine-phalloidin (F-actin) and
Hoechst (nuclei).
High content image analysis
Images obtained using the ImageXpress platform were processed for phenotypic analysis
within OMiner™ software (OcellO B.V.) integrated within the KNIME Analytics Platform
(Konstanz, Germany, http://www.knime.org/) as described previously [32, 33]. Briefly, this
software enabled the quantification of z-stack images derived from Hoechst and rhodamine-
phalloidin stained organoids. Information from both the DAPI and TRITC channels were
used to enhance organoid boundary separation. Masks generated from both channels facili-
tated the visualisation of main organoid structure, internal morphometries such as individual
lumens, as well as nuclei per organoid. Objects that were out of focus were filtered and dis-
carded from analysis. Morphological features were calculated on the basis of individual orga-
noids and pooled for analysis. Multiple features extracted included counts, total area, solidity,
and branching of nuclei, lumen and organoid masks.
Feature training between the negative control organoids and the high dose TNKSi treated
organoids was performed to condense the phenotypic features and calculate the Euclidian dis-
tance. The results are plotted with GraphPad Prism 7 (GraphPad Software, La Jolla, CA).
Results are shown as means ± standard deviations unless otherwise stated.
Quantitative real-time PCR
Total RNA was extracted from organoids resuspended in trizol solution (Life Technologies)
containing 125 μg/ml glycogen. cDNA was yielded from purified mRNA using ImProm II
Reverse Transcription kit (Promega). Quantitative-RT PCR was then performed using the
SensiFAST SYBR Green Hi-ROX master mix (Bioline). Primers were designed (Sigma
Aldrich) and listed in S2 Table. All samples were measured in triplicate, with gene expression
normalised to GAPDH housekeeping gene. Reactions were measured on a Step One Plus real-
time PCR instrument (Applied Biosystems) with relative changes in gene expression calculated
using the ΔΔCt method.
Wholemount immunofluorescent staining
Organoids were seeded as single cells in 96 well plates in 9 μL growth factor reduced Matrigel
at a density of 400 cells/μL. Following a six day exposure to compounds and control condi-
tions, organoids were fixed in 4% PFA for 15 min at room temperature. Wells were then
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washed with PBS containing 100 mM glycine prior to blocking overnight in PBS containing
10% horse serum, 0.1% Bovine Serum albumin, 0.2% Triton X-100, 0.05% Tween 20 then
stained with primary antibodies overnight (S1 Table) at 4˚C. Secondary antibodies were then
added overnight at 4˚C, prior to counterstaining with Hoechst. Wells were washed with PBS
then imaged on a confocal microscope, Leica TCS SP2 AOBS.
In vivo assessment of TNKS inhibitor efficacy
All mice were obtained commercially from Charles River and then housed under UK Home
Office regulations. The work described here was carried out under Home Office PPL 30/3279.
In vivo organoid engraftment studies (also termed “organoid derived xenografts” (ODX)) were
conducted using immune-deficient NOD/SCID gamma irradiated mice. For organoid trans-
plantation, organoids were in culture for 24 h from single cells prior to subcutaneous trans-
plantation into the right flank of the animal (one injection site per mouse). Mice were checked
every 2 days for tumour growth by palpation, according to Home office regulation protocol.
Palpable tumours (> 5 mm) were counted for use in Kaplan-Meier analysis. Cardiff Univer-
sity’s Animal Welfare and Ethical Review Body (AWERB) reviewed the plan for animal studies
prior to the grant of the Home Office License (30/3279). Animals in the study described were
killed by cervical dislocation (Schedule 1 method).
Results
Establishment of tumour organoids from CRC patient material
Surgically-resected CRC material was isolated from patients under informed consent. Cell
fragments were isolated from tissue and plated within growth factor- reduced matrigel within
24 hours following surgery, adapting methods previously described by Sato et al [20]. Two dif-
ferent culture conditions were used as standard; “7+ basal” and “full” growth factor rich
medium. Each condition was found to be optimal for a distinct subset of organoids (Fig 1A)
and allowed the efficient generation of organoids from what were in some cases limited
tumour cell numbers. Of 59 collected samples 48 were established in culture, a ‘take-rate’ of
>81% for organoid model derivation (organoids were denoted by Isolation number, ‘Iso-’).
Recent studies have similarly emphasised the requirement for different media to ensure effi-
cient organoid generation from different patients [21].
A subset of 10 organoids was studied in more detail. Optimal culture conditions were deter-
mined on the basis of organoid formation efficiencies and visual inspection of organoid integ-
rity. 8/10 organoid lines showed good growth in 7+ basal medium whilst 2/10 were dependent
on the additional inclusion of EGF (50 ng/ml), Noggin (100 ng/ml), Nicotinamide (10 mM),
A-83-01 (500 nM), SB202190 (10 μM), as well as Wnt3a- (40%) and R-spondin 1- (10%) con-
ditioned media. The organoid medium combinations shown in Fig 1A were used for subse-
quent studies. Full exome sequencing showed that the subset of 10 organoids contained
common genotypes found in other organoid banks (Fig 1A; S1 Appendix); [2, 34]. In particu-
lar, 80% of organoid lines harboured mutations in components of the Wnt signalling pathway,
such as APC and β -catenin (CTNNB1). Iso 75 was found to harbour a mutation in RNF43,
which is associated with an increased Frizzled (Fz) receptor expression and Wnt ligand depen-
dence [34, 35].
CRC organoids have previously been shown to display histological features in common
with the tumours from which they were derived. Paired histological samples from the orga-
noids described were compared to their parental tumours. Distinct morphologies were
observed ranging from lines that preferentially formed single epithelial cell layers with large
lumens containing apoptotic cells (Fig 1B; S1 Fig) to multi-layered organoids with small
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indistinct lumens. The organoids frequently retained key histopathological grading features
that were present within the original patient tumour epithelium. For example, Iso 72, was
established from a mucinous adenocarcinoma and displayed a high percentage of mucinous
vacuole structures that resembled that of the matching patient tissue. The retention of features
present within primary patient tumour tissue showed that many features of tumour morphol-
ogy could be retained without the need for a stromal compartment.
Fig 1. Generation and establishment of tumour organoids from CRC patient material. (A) Summary of parental tumour sites and Dukes’ Stages, organoid media
conditions, and mutation status of organoid lines identified in Whole Exome Sequencing analysis. (B) Representative Hematoxylin+Eosin (H&E) staining of FFPE
tissue sections from primary colorectal tumour patient material and organoid counterparts. Organoids were cultured for a minimum of 6 days prior to fixation and
embedding. Qualitative morphological similarities were observed between tumour and organoid pairs. Scale bar = 100 μm.
https://doi.org/10.1371/journal.pone.0235319.g001
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Tankyrase inhibition altered the growth of patient-derived organoids
To study CRC organoid responses to a Wnt pathway inhibitor, we utilised the tankyrase inhib-
itor (TNKSi), C1 (Fig 2A). After six days of treatment, AXIN2 and TNKS1/2 protein levels
were raised in a number of organoid lines (Fig 2B). TNKS normally targets AXIN2 and
TNKS1/2 for degradation and TNKSi treatment would be expected to stabilise levels of each
protein [5]. To assess the functional impact of Tankyrase inhibition on organoid growth, cell
viability assays were performed for 3 organoid lines; Iso 50, Iso 72 and Iso 75. As a measure of
toxicity in the normal cell setting, we also evaluated C1 response in healthy intestinal orga-
noids. Tumour and normal intestinal organoids were digested to near-single cells, or mechani-
cally dissociated into small fragments, embedded within growth-factor reduced Matrigel and
overlaid with growth media containing the TNKSi for six days prior to measuring relative
ATP levels (Cell Titer Glo 3D). C1, which has a cellular mechanistic EC50 of 2nM, showed par-
tial efficacy in reducing ATP levels and markedly different potency in the 3 CRC lines (Fig
2C–2G). C1 treatment in healthy intestinal organoids showed limited effects on metabolic
activity (S3 Fig). EC50 values in CRC lines ranged from 2nM to 1μM, but accurate values were
hard to establish due to assay variance and also because many cells survived, even in the pres-
ence of high concentrations of compound, leading to reduced assay windows. The partial sur-
vival of organoid cells after 6 days C1 treatment suggest that long-term AXIN2 and TNKS1/2
biomarker responses might be compromised by alterations in cellular composition. Immuno-
fluorescent staining showed reduced levels of the proliferation marker Ki67 in Iso 72 but not
Iso 50 organoids suggesting that reduced proliferation contributed to the lower ATP levels
observed (Fig 2H and 2I).
Multi-parametric phenotypic profiling of organoids in 3D to classify
responses to Tankyrase inhibition
To better understand the TNKSi partial efficacy, a novel multi-parametric 3D image workflow
analysis was used to characterise the morphological effects of the responses. Three Tankyrase
1/2 (TNKS1/2) small molecule inhibitors were used that differed over 3 orders of magnitude
in their potency (C1; 2nM, C2; 36nM, C3; 319nM Fig 2A). Organoids were seeded and treated
as previously for 6 days prior to fixation and staining with rhodamine-phalloidin (F-actin) and
Hoechst 33258 (DNA). Images were acquired using a high-content wide-field fluorescence
microscope as described previously [32, 36].
To characterise phenotypes, OMiner™ software (OcellO™) was used to extract morphologi-
cal features from 2D projections of the F-actin and nuclei-derived image stacks to generate
masks of individual organoids, internal lumen structures and nuclei. Image segmentation was
used to distinguish components of both channels and minimise any background signal (Fig
3A; S4 Fig). Overall shape and fluorescence intensity of individual organoid structures were
extracted on a well-by-well basis to generate approximately 600 quantified features. Such fea-
tures included information in regards to shape, size, boundaries and branching of organoid
lumens and nuclear shape.
To identify optimum features that could classify TNKSi responses, feature training and
Euclidian distance calculations were performed on each data set as previously described [36].
This reduced features into key differentiating components to generate a measure of distance
between highest C1 TNKSi doses and negative control (DMSO, 0.1%) conditions. The feature
collection that describes the compound-induced morphological change differs per organoid
model, but most frequently included organoid size changes, lumen shape and size, appearance
of dead cells and changes in nucleus morphology related to growth reduction, cell organization
and cell death induction (S5 Fig).
PLOS ONE 3D imaging of organoids identifies responses to Tankyrase inhibitors
PLOS ONE | https://doi.org/10.1371/journal.pone.0235319 August 18, 2020 9 / 20
Fig 2. Assessing the effects of Tankyrase inhibition on overall organoid viability. (A) Structures of three tankyrase inhibitors: MSC2524070A (C1),
MSC2572070A (C2) and MSC2501490A (C3), with corresponding EC50 values. (B) Western blot of eight organoid lines treated with C1 (15 nM) and harvested
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The morphometric analysis showed that TNKS inhibition resulted in phenotypic alterations
in Iso 38, Iso 72, Iso 75 and Iso 78 (Fig 3B). Importantly, the cellular morphometric responses
correlated with known cellular EC50 values across a range of potencies. Compounds C1, C2
and C3 that had EC50 values of 2 nM, 36 nM and 319 nM (Table 1) also showed the expected
separation of EC50 activities in the organoid morphometric assays, suggesting that observed
after 6 days. (C) Representative images of organoids treated with C1 (15 nM) or DMSO (scale bar = 100 μm). (D, E, F) Dose-response curves of organoids
treated with C1 for six days. Organoids previously established in suitable culture conditions were enzymatically digested to single cells and overlaid with media
containing a dose range of drug (0.195 nM– 50 nM), or a DMSO control (0.1% in media). Cell Titer Glo 3D readouts were performed in triplicates for Iso 50
(D), Iso 72 (E), Iso 75 (F). (G) EC50 values, obtained from (n = 3) experiments. Data are presented as mean ± S.E.M. (H, I) Representative immunofluorescent
staining of a proliferation marker in organoids. Iso 50 (H) and Iso 72 (I) with differential sensitivity to TNKSi were treated with C1 (25 nM) or DMSO (0.1%)
control for 6 days, fixed and stained with Ki67. Arrows indicate proliferating cell within the organoid, Ki67 positive-cells in Iso 72 only when treated with C1
(scale bar = 50 μm).
https://doi.org/10.1371/journal.pone.0235319.g002
Fig 3. 3D image analysis demonstrates target affinity of tankyrase inhibitors in organoids. (A) Flow diagram of high-content multi-parametric image screen process.
(B) Dose response curves acquired from high content imaging screen. Organoids were seeded as single cells in 384 well plates and exposed to Tankyrase inhibitors C1,
C2, C3 for six days. Individual morphological measurements were generated from DAPI and F-actin channels. Principal component analysis was used to select the top
10 most discriminating features to separate compound-induced phenotypes between high and low doses of Tankyrase inhibitors. Selected parameters were used for
feature space training, whereby Euclidean distance metrics were calculated between high and low doses of each compound for each organoid line. Euclidean distances
were used as an indicator of similarity between low and high doses, with a low distance indicative of high phenotypic similarity between conditions. Data are presented
as mean Euclidean distance from 8 replicate wells ± S.D.
https://doi.org/10.1371/journal.pone.0235319.g003
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effects were as a result of targeted inhibition of TNKS. Iso 72, Iso 75 and Iso 78, showed clear
differential dose-dependent potency for three compounds. Two additional lines, Iso 38 and Iso
34 showed partial separation of their morphological responses in line with the order of cellular
potency. Iso 50, Iso 48 and Iso49 showed no discernible responses. The effect sizes of the mor-
phometric responses compared very favourably with the noisier data from the ATP assays (Fig
2C).
Iso 75 and Iso 78 organoids required ‘full’ medium containing exogenous Wnt and R-spon-
din ligands for expansion in culture. Whole exome sequencing revealed that Iso 75 harboured
an RNF43 mutation (Fig 1A), which would likely yield organoids that require Wnt signalling
at the receptor level–upstream of the Axin-containing β-catenin turnover complex [35]. How-
ever, both Iso 72 and Iso 38 grew independently of Wnt and R-spondin suggesting that TNKSi
sensitivity is not necessarily as a result of exogenous Wnt conditions. Collectively, this data
indicates that 3D image based assays provide an accurate identification and quantification of
organoid responses to Wnt signalling modulators.
Sensitivity to Tankyrase inhibitors was associated with drug-induced
suppression of stem cell markers
Tankyrases promote the degradation of Axin, inducing β-catenin stabilization and activation
of Wnt signalling [5]. We therefore investigated the impact of TNKS inhibition on compo-
nents of the Wnt signalling pathway in the organoid lines. The cellular distribution of β-cate-
nin was assessed by immunofluorescence in organoids treated with C1 (15 nM for 6 days).
TNKS inhibition reduced total β-catenin levels in both TNKS sensitive (Iso 72 and Iso 75) and
non-sensitive lines (Iso 50; Fig 4A) suggesting that TNKSi were biochemically active in all
organoid lines. Quantitative RT-PCR was used to analyse gene expression changes in response
to TNKSi treatment for 6 days. Expression of DKK1 and ASCL2, two direct β-catenin target
genes [37], were reduced in all three lines although the effect size was greater in ASCL2 levels
of the TNKSi-sensitive lines Iso 72 and Iso 75 than in the TNKSi-insensitive line Iso 50
(p<0.001, Fig 4B). Taken together, this suggested that the loss of β-catenin was linked to
changes in gene expression, but not necessarily to functional responses. Changes in gene
expression which did correlate with functional TNKSi sensitivity included reductions in the
expression of the intestinal stem cell marker LGR5 and the upregulation of cytokeratin 20
(KRT20) (Fig 4B; S6 Fig), suggesting that tankyrase inhibition may induce differentiation as
has previously been shown with CRC cell lines [8].
Lgr5 immunostaining in the Iso 50, Iso 72 and Iso 75 lines correlated with the qRT-PCR
results (S6 Fig). Lgr5-positive cells were detected in both TNKSi-treated and untreated Iso 50
Table 1. Summary of EC50 values obtained by morphometric analysis.
EC50 (nM) C1 C2 C3
Cell line 2 36 300
Iso 34 3 75 No Fit
Iso 38 9 55 2000
Iso 48 No fit No fit No fit
Iso 49 No fit No fit No fit
Iso 50 No fit No fit No fit
Iso 72 2.6 36 346
Iso 75 3 31 1060
Iso 78 1.8 30 400
https://doi.org/10.1371/journal.pone.0235319.t001
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organoids, while Iso 72 and Iso 75 to TNKSi showed reductions in expression following
TNKSi treatment. Taken together, these results suggest that the pharmacological inhibition of
TNKS results in an overall reduction of Wnt/β-catenin signalling in both TNKSi-sensitive and
resistant organoid lines and that phenotypic responses could not be simply predicted based on
the expression of biomarkers. The best overall biomarker of organoid response may instead be
functional morphometric readouts, perhaps as a consequence of differential cellular responses
to the compounds being studied.
Fig 4. Tankyrase inhibition alters the proportion of stemness in CRC organoids. (A) Representative confocal images of organoids stained with
a β-catenin antibody following six days of exposure to C2 or control (DMSO, 0.1%) showing a reduction in the intensity and numbers of cells
showing β-catenin positivity following treatment (scale bar = 50 μm). (B). Quantitative real-time PCR analysis of relative mRNA expression of
intestinal epithelial markers from organoids (Iso 50, Iso 72, Iso 75) cultured with tankyrase inhibitor C1 (15 nM, 6 days) or DMSO (0.1%).
Markers associated with intestinal stem cell activity (LGR5, ASCL2), differentiation (KRT20, DKK1) alongside other members of the Wnt–
signalling pathway were determined, with mRNA expression normalized to control conditions. Experiments were performed in biological repeats
(n = 3) with error bars indicative of S.E.M (���, p�0.001; ��, p� 0.01; �, p�0.05, Paired Student’s t-test with Bonferroni correction).
https://doi.org/10.1371/journal.pone.0235319.g004
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Assessing the effects of Tankyrase inhibition in a patient organoid-derived
xenograft (ODX) model
The presence of cancer stem cells is often identified by transplantation of tumour cells within
immune-deficient animal models and subsequent formation of tumours [38]. To assess
whether both functional and phenotypic effects of TNKSi within the sensitive organoids
would translate to a reduction in tumour growth in vivo, an organoid-derived xenograft model
was generated from the TNKSi-sensitive line, Iso 75. Organoids were digested to single cells,
plated in Matrigel and immediately treated with TNKS inhibitor C1 (30 nM) or vehicle control
(DMSO, 0.1%) for 24 hours. Based on previous work showing rapid responses to Wnt pathway
inhibition [39], it was hypothesised that the pre-treatment of organoids would result in a tran-
scriptional effect as a result of Wnt signalling inhibition, altering the cancer stem cell function
of cells within the organoids.
Following treatment, small organoids were injected orthotopically into the flanks of 16
gamma-irradiated Non-Obese Diabetic/Severe Combined Immunodeficiency (NOD/SCID/γ)
mice, at one injection site per mouse (Fig 5A). Tumours grew from the injected organoids at
100% of sites injected. However, TNKSi pre-treated organoids showed significantly delayed
tumour formation by comparison with vehicle control (Fig 5B; Log Mantel-Cox test
Fig 5. TNKSi-treated organoids enhance survival in an organoid-derived xenograft (ODX) mouse model. (A)
Schematic diagram depicting organoid transplantation into mice. (B) A cohort of 16 NOD/SCID/ γ-irradiated mice
were injected with pre-treated (30 nM C2 for 24 hours) Iso 75 organoids, or control (0.1% DMSO, 24 hours) organoids
within one injection site per mouse. TNKSI-treated organoids showed a significant delayed formation of tumours
compared to control conditions (Log-Rank (Mantel-Cox) test P = 0.032.
https://doi.org/10.1371/journal.pone.0235319.g005
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p = 0.032), suggesting that the 24 hour TNKSi exposure was sufficient to reduce the capacity of
transplanted organoids to form tumours.
Discussion
3D organoids represent an attractive platform for the capture of the effects of therapies target-
ing signalling pathways involved in the regulation of complex morphometric interactions that
are not well represented in clonal 2D culture. Here, compounds targeting the Wnt/β-catenin
pathway were studied in patient derived CRC organoids using image-based analyses as previ-
ously described [32, 36]. Numerous morphometric features, such as the distance of the matrix
to central lumens and the number of nuclei per structure were quantified using automated
algorithms. Due to their biological complexity, multi-parameter sets of organoid-responses
may be able to characterise treatment-induced phenotypes that are linked to underlying signal-
ling and cell biological processes. For example, changes in the activity of regulators of cell line-
age will likely be reflected in alterations to the spatial organisation of cell types and organoid
morphology organoids [40]. However, predictions as to how any particular morphological
response is driven by alterations to specific biological mechanisms will require the develop-
ment of predictive multiscale mathematical models of organoid morphology and signalling
pathways [41].
Overall, morphometric analyses were found to improve assay windows by comparison with
biochemical assays, most likely by aggregating multiple phenotypic responses that sensitively
discriminate responses to drug treatments [32, 42].
The identification of a set of morphometric parameters that accurately distinguish between
compounds of different potency allowed putative biomarkers of TNKSi sensitivity to be com-
pared with organoid phenotypic responses. Single parameter functional readouts such as
TNKSi-induced alterations in ATP levels showed a reduced effect size by comparison with the
morphometric responses. Alterations in a range of alternative biomarkers correlated poorly
with morphometric responses. Alterations in the expression of stem cell marker genes includ-
ing ASCL2 and LGR5 correlated with cellular responses, but larger-scale studies will be
required to determine whether panels of gene expression markers reliably predict organoid
(and ultimately patient) responses. Confounding factors in these analyses are likely to be the
levels of stem cell gene expression, variation in the ‘stemness’ of tumours and the proportion
of cancer stem cells within tumour and corresponding organoid populations. Each of these
properties themselves are likely to be dynamically altered following compound treatment,
requiring detailed time-course analyses to deconvolute. By contrast, changes to developmental
trajectories induced by compounds such as TNKSi will leave a permanent record in each orga-
noid’s morphological structure.
Morphometric assays showed that Iso75, a line that required Wnt3a and R-spondin for
growth (mutant for RNF43 mutant and APC wild type), was sensitive to TNKSi as expected
[35]. However, a simple correlation between Wnt-dependence in culture and TNKSi sensitiv-
ity was not observed since 5 out of the 8 lines examined showed morphometric responses that
tracked the cellular potency of the TNKS inhibitors (Fig 3B). In particular, clear phenotypic
responses were observed in Iso 72 and 78, both of which were APC mutant and only one of
which required Wnt/Rspo-conditioned medium for growth.
Whilst it is mechanistically challenging to directly link Wnt inhibition via morphometric
responses to alterations in stem cell cycling, pre-treatment of a TNKSi sensitive organoid line
for 24h in vitro delayed subsequent tumour formation in vivo following transplantation. Taken
together with the reductions in Wnt target gene expression and β-catenin levels, this would
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suggest that modulation of Wnt signalling in a sensitive line was sufficient to limit the stem-
like signature of organoid cell populations.
Despite the benefits of using the morphometric assay formats described here to identify
clear responses to Wnt modulating therapies, key challenges remain to be addressed. From a
clinical perspective, further detailed investigation of Wnt modulators will be required to deter-
mine whether TNKS inhibitors can provide clinical benefit. Toxicity remains an issue with
inhibitors [8], however recent studies have suggested these might be reversible [43], such that
careful timing of Wnt-inhibitor treatment in combination with standard-of-care therapies
could identify rational therapeutic opportunities. When strategies targeting cancer stem cells
have been further developed, a robust in vitro readout such as organoid morphology may be
able to identify those patients who would benefit the most. Lastly, the imaging pipeline
described might be usefully applied in drug discovery screens, enabling the detection of com-
pounds that might otherwise have been rejected for lack of efficacy during pre-clinical drug
testing.
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